Summary of COVID-19 HuMax-IL8 studies

1. Stein et al., A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19

43 patient HuMax-IL8 late treatment RCT: 6% higher mortality (p=1), 100% higher ICU admission (p=0.59), and 107% slower improvement (p=0.08).
RCT 43 hospitalized patients in the USA showing no significant benefit with HuMax-IL8 (BMS-986253) treatment.
May 2025, NCT04347226, https://clinicaltrials.gov/study/NCT04347226, https://c19p.org/stein